Expanded access policy
Crescent Biopharma, Inc. is a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients. We are committed to conducting clinical trials to evaluate the safety and efficacy of our investigational therapies. These trials are essential to obtaining the required marketing approvals that enable physicians to prescribe these therapies and support broad patient access.
In some circumstances, a treating physician may make a request to provide an unapproved therapy to a qualifying individual, which must be approved by the U.S. Food and Drug Administration (FDA) and supported by the pharmaceutical manufacturer. This is called an expanded access program (EAP), sometimes known as “compassionate use,” and refers to a potential pathway for a patient with a serious or life-threatening disease or condition to try an investigational therapy outside of a clinical trial when there is no comparable or satisfactory therapy available.
We currently have investigational therapies in our pipeline for the treatment of cancer. While we understand that some patients may wish to access our unapproved investigational therapies, our goal is to provide access to our therapies at the appropriate time and in a manner that is most beneficial to the relevant patient population. At this stage of our development, Crescent does not currently offer an expanded access program. We believe enrollment in our ongoing clinical trials is the safest and most effective way of obtaining access to Crescent’s investigational therapies and we encourage all patients and physicians who are interested in accessing our investigational therapies to visit the clinicaltrials.gov website to find out about enrolling.
Crescent may revise this expanded access policy at any time. Additionally, the posting of this policy by Crescent does not serve as a guarantee of access to any specific investigational new drug by any individual patient.
If you have any questions, please reach out to us at clinicaltrials@crescentbiopharma.com.